Accelerate to discover

Back to filter

Related topics

Preclinical lung imaging offers effective evaluation of drug candidates

Bruker Biospin

Mar 1, 2021

The incidence of respiratory disease is increasing throughout the world, and the demand for safe, effective drugs to...

Curiox Laminar Wash technology to become a gold standard for TotalSeq Protocol.

Curiox

Feb 15, 2021

Curiox Laminar Wash technology has been added as part of the official BioLegend TotalSeq Protocol. It makes processing...

Amnis CellStream's new software features - now better than ever

Luminex

Feb 12, 2021

It's finally here, and better than ever - Amnis CellStream's Acquisition and Analysis Software update increases ease of...

Towards silent and distortion-free fMRI with Zero Echo Time MRI

Bruker Biospin

Feb 9, 2021

By using fast imaging techniques capable of scanning large brain regions within short durations, continuous snapshots...

Mar 3, 2021

STAT Protein Phosphorylation in CD4+ T Cells using the CellStream flow cytometer

Luminex

Jan 21, 2021

Cytokine-induced protein phosphorylation is a key cell signaling event within the immune system that modulates diverse...

Introducing Cytek cFluor, 14 Colors Immunoprofiling Kit

Cytek Biosciences

Jan 19, 2021

Cytek cFluor Immunoprofiling Kit allows for the identification of helper T cells, cytotoxic T cells, B cells, NK cells...

A Glimpse on physiological monitoring for the in vivo SKYSCAN Systems

Bruker Biospin

Jan 14, 2021

This past year has proven once again that in vivo imaging is an important aspect in the microCT world. For longitudinal...

Mar 3, 2021

High gain mode now available on the Amnis ImageStreamX Mk II

Luminex

Dec 31, 2020

Increase camera gain during data acquisition and dramatically increase photonic sensitivity with High Gain mode, a new...

Show all topics (10)

Better antibody discovery using IntelliCyt’s iQue Screener

May 18, 2016

With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.

Read more

 

Scientific paper
Product news

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

IntelliCyt

IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey